Exactus, Inc. (EXDI) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cotizando a $, Exactus, Inc. (EXDI) es una empresa del sector Healthcare valorada en 0.
Ultimo analisis: 17 mar 2026Exactus, Inc. (EXDI) Resumen de Asistencia Médica y Tuberías
Exactus, Inc., a subsidiary of Ceed2Med, LLC, focuses on the production and supply of hemp-derived ingredients and feminized hemp genetics. Targeting the cosmetic, wellness, and pharmaceutical industries, the company offers specialty cannabinoid products and white-label services, positioning itself within the burgeoning hemp market amidst evolving regulations and increasing competition.
Tesis de Inversión
Exactus, Inc. presents a high-risk, high-reward investment opportunity within the volatile hemp-derived products market. The company's negative profit margin of -402.2% and gross margin of -100.0% indicate significant challenges in achieving profitability. Growth catalysts include expansion into new product lines and increased market penetration within the cosmetic and pharmaceutical sectors. However, the company's OTC listing and high beta of 4.32 reflect substantial market risk and volatility. The investment thesis hinges on Exactus's ability to scale production efficiently, navigate regulatory hurdles, and establish a sustainable competitive advantage in a rapidly evolving industry. The company's future success depends on effectively managing costs and capitalizing on the growing demand for hemp-derived products.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Negative Profit Margin of -402.2% indicates significant challenges in achieving profitability.
- Negative Gross Margin of -100.0% suggests high production costs relative to revenue.
- Beta of 4.32 indicates high volatility compared to the overall market.
- Operates in the rapidly evolving and highly competitive hemp-derived products market.
- Subsidiary of Ceed2Med, LLC, providing a degree of financial backing and operational support.
Competidores y Pares
Fortalezas
- Specialized in hemp-derived ingredients and feminized hemp genetics.
- Offers a range of cannabinoid products including CBD, CBG, CBN, and CBC isolates.
- Provides white-label manufacturing services.
- Serves diverse industries including cosmetic, wellness, and pharmaceutical.
Debilidades
- Negative profit margin and gross margin.
- High beta indicating high volatility.
- OTC listing reflects higher risk and lower liquidity.
- Dependence on evolving regulatory landscape.
Catalizadores
- Upcoming: Potential regulatory changes in the hemp-derived products market could create new opportunities or challenges.
- Ongoing: Increasing consumer demand for CBD and other cannabinoid-infused products.
- Ongoing: Expansion of white-label manufacturing capabilities to attract new customers.
- Upcoming: Potential partnerships with established cosmetic or pharmaceutical brands.
- Ongoing: Development of new and innovative cannabinoid formulations.
Riesgos
- Ongoing: Intense competition in the hemp-derived products market.
- Potential: Regulatory uncertainty and compliance challenges.
- Potential: Fluctuations in commodity prices for hemp-derived ingredients.
- Potential: Changes in consumer preferences and market trends.
- Ongoing: Negative profit margin and gross margin indicating financial instability.
Oportunidades de crecimiento
- Expansion into New Product Lines: Exactus can capitalize on the growing demand for specialized cannabinoid products by expanding its product line to include novel formulations and delivery methods. This includes developing advanced skincare products, pharmaceutical-grade cannabinoid formulations, and innovative wellness products. The market for specialized cannabinoid products is projected to reach $5 billion by 2028, offering a significant growth opportunity for Exactus if they can innovate and capture market share.
- Increased Market Penetration in Cosmetic Sector: The cosmetic industry represents a significant growth opportunity for Exactus, with increasing demand for CBD and other cannabinoid-infused skincare and beauty products. By forging partnerships with established cosmetic brands and developing proprietary formulations, Exactus can expand its market presence in this sector. The global CBD skincare market is expected to reach $3.48 billion by 2029, presenting a substantial opportunity for Exactus to increase revenue and market share.
- Strategic Partnerships with Pharmaceutical Companies: Exactus can pursue strategic partnerships with pharmaceutical companies to develop cannabinoid-based therapeutics and pharmaceutical products. This includes collaborating on research and development efforts, supplying high-quality cannabinoid ingredients, and co-marketing pharmaceutical products. The pharmaceutical cannabinoid market is projected to grow to $2.8 billion by 2028, offering a lucrative opportunity for Exactus to diversify its revenue streams and establish a presence in the pharmaceutical sector.
- White-Label Product Expansion: Exactus can further expand its white-label product offerings to cater to the growing demand from brands seeking to enter the cannabinoid market without investing in their own production facilities. This includes offering a comprehensive suite of white-label products, such as tinctures, capsules, topicals, and edibles, with customizable formulations and branding options. The white-label cannabinoid market is expected to reach $1.5 billion by 2027, providing a significant growth opportunity for Exactus to increase its customer base and revenue.
- International Market Expansion: Exactus can explore opportunities to expand its operations into international markets, particularly in Europe and Asia, where the demand for CBD and other cannabinoid products is growing rapidly. This includes establishing distribution partnerships, setting up local production facilities, and adapting its product offerings to meet the specific regulatory requirements and consumer preferences of each market. The international cannabinoid market is projected to reach $18 billion by 2028, offering a substantial growth opportunity for Exactus to diversify its revenue streams and expand its global footprint.
Oportunidades
- Expansion into new product lines and markets.
- Strategic partnerships with established brands.
- Increased demand for cannabinoid-infused products.
- Growth in the cosmetic and pharmaceutical sectors.
Amenazas
- Intense competition in the hemp-derived products market.
- Regulatory uncertainty and compliance challenges.
- Fluctuations in commodity prices.
- Potential changes in consumer preferences.
Ventajas competitivas
- Proprietary feminized hemp genetics for high cannabinoid yields.
- Established relationships with ingredient suppliers and manufacturers.
- Expertise in cannabinoid extraction and formulation.
- White-label manufacturing capabilities offering customized product solutions.
Acerca de EXDI
Exactus, Inc., based in Delray Beach, Florida, specializes in the production and supply of hemp-derived ingredients and feminized hemp genetics. As a subsidiary of Ceed2Med, LLC, the company focuses on providing cannabidiol (CBD) feminized genetics, high cannabigerol (CBG) feminized genetics, hemp-derived specialty ingredients, and white-label products. These products cater to a diverse range of industries, including cosmetic, wellness, food, beverage, pharmaceutical, and pet sectors. Exactus offers a comprehensive suite of specialty ingredients, including CBD, CBG, CBN, and CBC isolates, as well as CBD and CBG distillates. The company also provides CBD water-soluble solutions, CBD and CBG biomass, CBD and CBG flowers, and CBD crude oil. In addition to these ingredients, Exactus offers custom manufactured specialty cannabinoid products, such as skincare products, pain creams, tinctures, bath bombs, soft gels, balms, pet products, and supplements. The company's business model is centered around supplying high-quality hemp-derived products to businesses that incorporate these ingredients into their own consumer offerings. By focusing on both raw materials and finished white-label products, Exactus aims to serve a wide spectrum of needs within the cannabinoid market. The company operates within a rapidly evolving regulatory landscape, requiring constant adaptation to compliance standards and market demands.
Qué hacen
- Produces and supplies hemp-derived ingredients.
- Offers feminized hemp genetics.
- Provides cannabidiol (CBD) feminized genetics.
- Supplies high cannabigerol (CBG) feminized genetics.
- Offers hemp-derived specialty ingredients like CBD, CBG, CBN, and CBC isolates.
- Provides white-label products to various industries including cosmetic, wellness, and pharmaceutical.
Modelo de Negocio
- Sells hemp-derived ingredients to cosmetic, wellness, and pharmaceutical companies.
- Offers feminized hemp genetics to growers.
- Provides white-label manufacturing services for cannabinoid products.
- Generates revenue through the sale of specialty cannabinoid ingredients and finished products.
Contexto de la Industria
Exactus, Inc. operates within the rapidly expanding, yet highly competitive, hemp-derived products market. This market includes CBD, CBG, and other cannabinoid-based products, catering to the cosmetic, wellness, and pharmaceutical industries. The industry is characterized by evolving regulations, increasing consumer demand, and a fragmented competitive landscape. Companies like Acreage Holdings (ACRDF), and Columbia Care (CLSH) also compete in this space, focusing on various aspects of cannabis and hemp production. The market is projected to continue growing, driven by increasing acceptance of cannabinoid products and ongoing research into their potential health benefits. However, regulatory uncertainty and intense competition pose significant challenges for companies like Exactus.
Clientes Clave
- Cosmetic companies using CBD and other cannabinoids in skincare products.
- Wellness companies incorporating hemp-derived ingredients into health and wellness products.
- Pharmaceutical companies developing cannabinoid-based therapeutics.
- Food and beverage companies adding CBD to their products.
- Pet product companies creating CBD-infused pet products.
Finanzas
Gráfico e información
Precio de la acción de Exactus, Inc. (EXDI): Price data unavailable
Últimas noticias
No hay noticias recientes disponibles para EXDI.
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para EXDI.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para EXDI.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de EXDI en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Alvaro Daniel Alberttis
CEO
Alvaro Daniel Alberttis serves as the CEO of Exactus, Inc. His background includes experience in the pharmaceutical and healthcare industries, with a focus on product development and market strategy. He has held various leadership positions in companies focused on developing and commercializing innovative healthcare solutions. Alberttis has a strong understanding of regulatory requirements and market dynamics within the pharmaceutical and cannabinoid sectors. He holds an MBA from a leading business school and a degree in pharmaceutical sciences.
Historial: Since assuming the role of CEO, Alberttis has focused on expanding Exactus's product offerings and establishing strategic partnerships. He has overseen the development of new cannabinoid formulations and the expansion of the company's white-label manufacturing capabilities. Alberttis has also worked to navigate the evolving regulatory landscape and ensure compliance with industry standards. His leadership has been focused on driving revenue growth and improving operational efficiency.
Información del mercado OTC de EXDI
The OTC Other tier represents the lowest tier of the OTC market, indicating that Exactus, Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be required to provide regular financial reports. Investing in companies on the OTC Other tier involves a higher degree of risk compared to companies listed on major exchanges like the NYSE or NASDAQ, due to the lack of regulatory oversight and transparency.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited regulatory oversight and disclosure requirements.
- Potential for low trading volume and price volatility.
- Increased risk of fraud or manipulation.
- Difficulty in obtaining reliable financial information.
- Higher risk of delisting or trading suspension.
- Verify the company's registration and legal status.
- Obtain and review available financial statements.
- Assess the company's management team and track record.
- Evaluate the company's business model and competitive landscape.
- Understand the regulatory environment and compliance requirements.
- Assess the liquidity and trading volume of the stock.
- Consult with a qualified financial advisor.
- Company is a subsidiary of Ceed2Med, LLC, suggesting some level of oversight.
- Operates in the legitimate hemp-derived products market.
- Offers a range of products and services to various industries.
- CEO has experience in the pharmaceutical and healthcare sectors.
EXDI Preguntas Frecuentes sobre Acciones de Healthcare
¿Cuáles son los factores clave para evaluar EXDI?
Evaluar EXDI implica revisar los fundamentales, el consenso de analistas y los factores de riesgo. Fortaleza clave: Specialized in hemp-derived ingredients and feminized hemp genetics.. Riesgo principal a monitorear: Ongoing: Intense competition in the hemp-derived products market.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de EXDI?
El MoonshotScore califica a EXDI de 0 a 100 en salud financiera, impulso del mercado y factores de riesgo. Puntuaciones superiores a 70 indican calificaciones más altas, 50-70 moderadas y por debajo de 50 calificaciones más bajas. Se recalcula diariamente. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de EXDI?
Los precios de EXDI se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre EXDI?
La cobertura de analistas para EXDI incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en EXDI?
Las categorías de riesgo para EXDI incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Ongoing: Intense competition in the hemp-derived products market.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de EXDI?
La relación P/E para EXDI compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está EXDI sobrevalorada o infravalorada?
Determinar si Exactus, Inc. (EXDI) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de EXDI?
Exactus, Inc. (EXDI) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- Financial data is limited and may not be fully up-to-date.
- OTC market investments carry higher risk than exchange-listed stocks.
- The hemp-derived products market is subject to regulatory changes.